Key result
In patients with metastatic renal cell carcinoma treated with sunitinib, a soluble VE-cadherin variation <120% after one cycle was associated with longer progression-free survival.
Why the study?
Does sunitinib treatment alter soluble VE-cadherin levels, and do these changes predict clinical response in patients with metastatic renal cell carcinoma?
Cohort (n=131)
Yes
Does sunitinib treatment alter soluble VE-cadherin levels, and do these changes predict clinical response in patients with metastatic renal cell carcinoma?
Soluble VE-cadherin is a direct target of sunitinib, and its early decrease in serum may serve as a predictive biomarker for progression-free survival in metastatic renal cell carcinoma.
Answers are grounded in this paper and cite their sources.
Early sunitinib-induced VE-cadherin changes may predict PFS in mRCC; leaves open prospective validation before clinical adoption.
BACKGROUND: in its cytoplasmic domain, and cleavage of its extracellular domain (sVE). In hormone-refractory metastatic breast cancer, we recently demonstrated that sVE levels correlate to poor survival. In the present study, we determine whether kidney cancer therapies had an effect on VE-cadherin structural modifications and their clinical interest to monitor patient outcome. METHODS: The effects of kidney cancer biotherapies were tested on an endothelial monolayer model mimicking the endothelium lining blood vessels and on a homotypic and heterotypic 3D cell model mimicking tumour growth. sVE was quantified by ELISA in renal cell carcinoma patients initiating sunitinib (48 patients) or bevacizumab (83 patients) in the first-line metastatic setting (SUVEGIL and TORAVA trials). RESULTS: Human VE-cadherin is a direct target for sunitinib which inhibits its VEGF-induced phosphorylation and cleavage on endothelial monolayer and endothelial cell migration in the 3D model. The tumour cell environment modulates VE-cadherin functions through MMPs and VEGF. We demonstrate the presence of soluble VE-cadherin in the sera of mRCC patients (n = 131) which level at baseline, is higher than in a healthy donor group (n = 96). Analysis of sVE level after 4 weeks of treatment showed that a decrease in sVE level discriminates the responders vs. non-responders to sunitinib, but not bevacizumab. CONCLUSIONS: These data highlight the interest for the sVE bioassay in future follow-up of cancer patients treated with targeted therapies such as tyrosine-kinase inhibitors.
No takes yet. Share an insight, caveat, or question.
Polena et al. (2018) conducted a cohort in Metastatic renal cell carcinoma (mRCC) (n=131). Soluble VE-cadherin (sVE) variation <120% after 1 cycle of sunitinib vs. sVE variation >120% after 1 cycle of sunitinib was evaluated on Progression-free survival (median months) (HR 0.2452, 95% CI 0.08452-0.7114, p=0.0097). In patients with metastatic renal cell carcinoma treated with sunitinib, a soluble VE-cadherin variation <120% after one cycle was associated with longer progression-free survival.
Synapse has enriched 10 related papers. Consider them for comparative context: